Theravance Biopharma, INC Form 4 insider transactions

Aine Miller, SVP at Theravance Biopharma, disposed of 11,295 ordinary shares to cover tax obligations related to vesting restricted stock units.

Brett A. Grimaud, SVP, General Counsel, and Secretary of Theravance Biopharma, Inc., disposed of shares to cover tax obligations related to vesting restricted stock units.

Rhonda Farnum, SVP, COMM & MEDICAL AFFAIRS at Theravance Biopharma, reports the vesting of performance-based restricted stock units and shares withheld for tax obligations.

Rhonda Farnum, SVP at Theravance Biopharma, sold 4,000 ordinary shares at $9 each, as part of a pre-arranged 10b5-1 trading plan.

Theravance Biopharma's CEO, Rick E. Winningham, sold 15,997 shares to cover tax obligations related to vesting restricted stock units.

Aziz Sawaf, SVP & CFO of Theravance Biopharma, sold 8,477 ordinary shares to cover tax obligations related to vesting restricted stock units.

Theravance Biopharma's SVP, Aine Miller, sold 10,076 ordinary shares to cover tax obligations related to vesting restricted stock units.

A Theravance Biopharma executive, Brett A. Grimaud, sold 9,268 shares to cover tax obligations related to vesting restricted stock units.

A Theravance Biopharma executive, Rhonda Farnum, sold 9,178 shares to cover tax obligations related to vesting restricted stock units.

Theravance Biopharma's CEO, Rick E. Winningham, acquired 3,193 ordinary shares at $9.57 per share, in a transaction reported late due to an administrative error.

Rhonda Farnum, SVP at Theravance Biopharma, sold 4,000 ordinary shares at $9 each, according to a recent SEC filing.

CEO Rick Winningham of Theravance Biopharma reports disposal of shares to cover tax obligations related to vesting restricted stock units.

Aziz Sawaf, CFO of Theravance Biopharma, disposed of 8,635 ordinary shares to cover tax obligations related to vesting restricted stock units.

Aine Miller, SVP at Theravance Biopharma, disposed of 5,201 ordinary shares to cover tax obligations related to vesting restricted stock units.

Brett A. Grimaud, SVP, General Counsel, and Secretary of Theravance Biopharma, Inc., reported disposing of 9,268 ordinary shares to cover tax obligations related to vesting restricted stock units on August 20, 2024.

Rhonda Farnum, SVP at Theravance Biopharma, reports disposition of shares to cover tax obligations.

Theravance Biopharma's CEO, Rick E. Winningham, acquired 3,252 ordinary shares at $7.83 per share under the company's Amended and Restated 2013 Equity Incentive Plan.

Director Eli Samaha reports purchasing $999,800 worth of Theravance Biopharma (TBPH) common stock on August 7, 2024.

Rhonda Farnum, SVP at Theravance Biopharma, reports the sale of 4,000 ordinary shares at $9 per share on July 10, 2024, according to a Form 4 filing.

CEO Rick Winningham of Theravance Biopharma reports disposing of shares to cover tax obligations related to vested restricted stock units.

Aziz Sawaf, SVP & CFO of Theravance Biopharma, disposed of 8,635 ordinary shares to satisfy tax obligations related to vesting restricted stock units.

Aine Miller, SVP at Theravance Biopharma, disposed of 5,201 ordinary shares to cover tax obligations related to vesting restricted stock units.

Brett A. Grimaud, SVP, General Counsel, and Secretary of Theravance Biopharma, Inc., disposed of 9,268 shares to cover tax obligations arising from vesting restricted stock units.

Rhonda Farnum, SVP at Theravance Biopharma, reports disposing of shares to cover tax obligations related to vesting restricted stock units.

Theravance Biopharma's CEO, Rick E. Winningham, acquired 2,068 ordinary shares at $9.85 per share under the company's equity incentive plan.

Director Deepika Pakianathan reports acquisition of shares and disposal of shares in Theravance Biopharma, Inc.

Director Donal O'Connor reports acquisition of shares and grant of share options in Theravance Biopharma.

Dean J. Mitchell, a director at Theravance Biopharma, reported the acquisition of 10,537 ordinary shares and 23,576 share options, as well as the disposal of 80,555 ordinary shares on May 8, 2024.

Susannah Gray, a director at Theravance Biopharma, acquired shares and options in the company on May 8, 2024.

Director Jeremy T Grant reports acquisition of Theravance Biopharma shares and options in a recent SEC filing.